-
In July 2014, new drug R & D achievements of listed pharmaceutical companies were gratifying
Time of Update: 2020-04-03
Among them, Zhejiang Zhenyuan has benefited a lot Four varieties have obtained new drug certificates or entered the administrative approval process Zhejiang Zhenyuan applied for the development of the
-
Watson biological "intravenous immunoglobulin (pH4)" drug clinical research registration application accepted
Time of Update: 2020-04-03
In the afternoon of January 29, Watson biology announced that the application for clinical research registration of "intravenous human immunoglobulin (pH4)" of Hebei Da'an Pharmaceutical Co., Ltd., th
-
Approved production of Lansoprazole for injection
Time of Update: 2020-04-03
According to the website of CFDA on April 11, the status of Lansoprazole for injection of class 3 new drugs of Jiangsu Wuzhong Pharmaceutical Group changed to "certificate preparation completed - appr
-
Two new hepatitis B projects of guangshengtang failed to be approved
Time of Update: 2020-04-03
In April 2014, China Securities Regulatory Commission disclosed the prospectus of Fujian guangshengtang Pharmaceutical Co., Ltd (hereinafter referred to as "guangshengtang") This enterprise, which spe
-
Clinical approval for tenofovir dipivoxil fumarate, a new drug of Anke in the treatment of AIDS
Time of Update: 2020-04-03
Tenofovir fumarate dipivoxil (tablets) is a nucleotide reverse transcriptase inhibitor, which is mainly used in the treatment of AIDS, hepatitis B and other diseases The drug was first developed by Gi
-
Irbesartan tablets approved by FDA
Time of Update: 2020-04-03
Haizheng Pharmaceutical (600267) announced in the evening of Friday (June 24) that the new drug of irbesartan tablets of Haizheng Pharmaceutical (Hangzhou) Co., Ltd., a wholly-owned subsidiary of the
-
Beijing green bamboo AC Hib triple vaccine, a subsidiary of Zhifei biology, is about to obtain production approval
Time of Update: 2020-04-03
The AC Hib triple vaccine independently developed by Beijing green bamboo bio Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd., is expected to rece
-
Raw materials and tablets approved
Time of Update: 2020-04-03
Approval for clinical trial of drugs: approval for clinical trial of drugs obtained from raw materials and tablets of rivaroxaban, a subsidiary Recently, Zhejiang Jinhua kangenbe biopharmaceutical Co.
-
Application for clinical research registration of a new drug of Hainan Haiyao for anti renal fibrosis was accepted
Time of Update: 2020-04-03
Haikou Pharmaceutical Factory Co., Ltd., a wholly-owned subsidiary of Hainan Haiyao Co., Ltd (hereinafter referred to as "Haikou pharmaceutical factory") and Central South University jointly applied f
-
The patent for podophyllotoxin, a new anti-tumor drug of Jianfeng pharmaceutical, was approved
Time of Update: 2020-04-03
Zhejiang Jianfeng Pharmaceutical Co., Ltd., the holding subsidiary of Jianfeng group, has issued a patent certificate for the patent "a preparation method of deoxypodophyllotoxin" It is understood tha
-
Shanghai Kaibao's exclusive new product Tanreqing capsule
Time of Update: 2020-04-03
Shanghai Kaibao said on the interactive platform of investor relations that the company's exclusive new product, Tanreqing capsule, has been put into production and is preparing for listing Tanreqing
-
Kangzhe Pharmaceutical Co., Ltd. disclosed the preliminary results of clinical research on casein for injection
Time of Update: 2020-04-03
Kangzhe Pharmaceutical Co., Ltd disclosed the preliminary results of a randomized, double-blind, placebo-controlled multicenter clinical study on the safety and efficacy period of casein for injection
-
Changchun high tech Jinsai Pharmaceutical Co., Ltd. gained clinical approval for new indication of long-term growth hormone
Time of Update: 2020-04-03
According to the website of the State Food and drug administration, the latest status of pegylated recombinant human growth hormone injection (referred to as long-acting growth hormone) applied for cl
-
Guilin Sanjin Pharmaceutical Co., Ltd. obtained approval for clinical trial on recombinant anti EGFR human mouse chimeric monoclonal antibody injection
Time of Update: 2020-04-03
Guilin Sanjin (SZ: 002275): Recently, it was announced that the recombinant anti EGFR human mouse chimeric monoclonal antibody injection was approved for clinical trial, Guilin Sanjin Pharmaceutical C
-
Phase II clinical development and supplement of puquitinib mesylate
Time of Update: 2020-04-03
The delivery information of puquitinib mesylate appeared in Xinchang pharmaceutical factory of Zhejiang Pharmaceutical Co., Ltd on February 17, which is likely to be a clinical supplement and needs th
-
Kunshan ruiboquark pharmaceutical technology completed 45 million RMB round a financing to accelerate the clinical development of qpi-1007
Time of Update: 2020-04-03
Deqi medical's first domestic PD-1 was approved for market priority review and encouraged children's drug research / * 300 * 250, which was founded on May 8, 2014 * / var cpro_id = "u1548962"; the recommended new drug express ly09004 was approved for clinical use, and LVYE pharmaceutical accelerated the global distribution of biological drugs in 2019 New Year's first single!
-
Great progress in three new heavy drugs of HongRi pharmaceutical industry
Time of Update: 2020-04-03
In fact, due to the speed of new drug evaluation, the speed of a new anti-cancer drug PTS and a new vascular drug fondaparinux is relatively slow PTS has been applied for production in the third quart
-
Tonghua Dongbao's first three generations of insulin glargine obtained clinical approval within months
Time of Update: 2020-04-03
According to the information on June 3 on the website of the State Food and Drug Administration (CFDA), the third-generation insulin glargine bulk drug and preparation insulin glargine injection that
-
Imatinib mesylate, a 3-class antitumor drug of Zhongqi pharmaceutical, a subsidiary of Shiyao group, has entered the site for on-site inspection
Time of Update: 2020-04-03
According to the website of CFDA on June 11, imatinib mesylate, a class 3.1 chemical applied for production by Zhongqi pharmaceutical, a subsidiary of Shiyao group, entered the site for inspection If
-
The first HFMD vaccine in China will enter the field for inspection and is expected to be approved within this year
Time of Update: 2020-04-03
According to the information on the website of CFDA on May 11, the inactivated enterovirus 71 vaccine (human diploid cells) from the Institute of medical biology, Chinese Academy of medical sciences w
